Investorideas.com - Biotech Stocks Update; UV Flu Technologies (OTCBB: UVFT) Announces Growth of National Distributor Network for UV-400 Bacteria Killing Air Purifier
Specialty Distributors Significantly Increase Target Market Penetration
CENTERVILLE, MA – November 2, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce the recent signing of agreements with 3 new distributors to commence offering the ViraTech UV-400 to their market segment commercial accounts.
The new distributors include Emerald Medical Service, a supplier of medical equipment throughout the Washington, DC area, UV Air, a supplier to government, schools, and hotels in the Woburn, MA area, and Factory-Direct Green, a distributor servicing over 400 hotel customers in the Carlsbad, California area.
"These agreements represent the beginning of our national initiative to add key representatives and distributors to cover our 5 primary target markets and segments. We identify those markets in no particular order as: Hospitality, including hotels, casinos, and spas; Medical, including hospitals, medical offices and nursing homes; the Government sector, which includes a huge inventory of installations, schools, Indian reservations and government offices; Athletics, including health clubs and sports teams; and Volatile Organic Compound (VOC) locations, which include many salons, laboratories and funeral homes," said Jack Lennon, President of UV Flu.
Mr. Lennon continues, "These new distributors have existing relationships in their respective segments, and are all actively diversifying their reach. As an example, we have been advised that just this week UV Air added Tactical Office Solutions in Woburn, MA to their client list. Tactical is an organization owned and operated by a disabled service veteran, and works exclusively within the government sector. With this in mind, UV Flu has begun all appropriate steps towards full eligibility under government procurement processes. With the addition of our new distributors, the Company is confident it will be announcing national accounts, including government contracts in the near future."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the UVFT showcase profile at Investorideas.com: http://www.investorideas.com/CO/UVFT/
Request News and Info on UVFT: http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.uvflutech.com
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com. (showcase biotech stock for one month advertising three thousand)
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Tuesday, November 2, 2010
Monday, November 1, 2010
Investorideas.com - Featured Biotech/Pharma Stock Profile Update for Biotech Investors; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
Investorideas.com - Featured Biotech/Pharma Stock Profile Update for Biotech Investors; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
Recent Key Highlights; BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
Visit this company: www.biosantepharma.com
Point Roberts, WA, LINCOLNSHIRE, Ill - November 1, 2010 (Investorideas.com newswire, www.biotechindustrystocks.com) updates the showcase biotech stock profile for BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for investors following biotech and pharma stocks.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) reports recent news; "BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation."
The BPAX company profile is available at http://www.investorideas.com/CO/BPAX/ for interested biotech investors.
Full Media Kit at: http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf
Company Overview:
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration(FDA) Special Protocol Assessment and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in PhaseII clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies.
Lead Products – Multi-Billion Dollar Markets
BioSante is focused on developing innovative products for female sexual health and oncology. The current market for testosterone and estrogen products is approximately $2.5 billion dollars in the U.S. alone, with estimates for female sexual dysfunction (FSD) potentially adding more than $2.0 billion. In addition, the current market for hormonal contraception is approximately $3.0 billion. The market for oncology products is over $20 billion.
BioSante’s lead near term product in development is LibiGel® (testosterone gel) for the treatment of FSD. LibiGel’s clinical development program consists of two Phase III safety and efficacy trials, being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Each trial will enroll approximately 500 surgically menopausal women for six months of treatment in double-blind placebo-controlled trials. Also ongoing is one Phase III cardiovascular events-driven safety study, enrolling between 2,500 and 4,000 women with cardiovascular risk factors, on therapy for one year and then followed for an additional four years after New Drug Application (NDA) submission and potential FDA approval. To date, over 2,500 women have been enrolled in the safety study. A completed LibiGel Phase II clinical trial has shown excellent results with a significant 238% increase in the total number of satisfying sexual events. There are currently no pharmaceutical products approved for the treatment of FSD in the U.S. however over 4 million prescriptions for testosterone were written off-label by physicians for women in 2009.
BioSante’s marketed product, ElestrinTM, is FDA approved to reduce hot flashes in menopausal women. The lower of the two approved Elestrin doses is 67% lower than the lowest dose transdermal patch available for the treatment of hot flashes. Elestrin is marketed in the U.S. by Azur Pharma.
BioSante is focused primarily on LibiGel, however, the Company also is seeking future development opportunities for its cancer vaccines, which are non patient-specific therapies comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety and are administered via intradermal injections on an outpatient basis. Currently, several of BioSante’s cancer immunotherapies are in Phase II clinical trials at Johns Hopkins Cancer Center and BioSante has been granted FDA Orphan Drug designation for its pancreatic cancer, acute myloid leukemia and chronic myeloid leukemia vaccines.
Recent Company News:
BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
"LINCOLNSHIRE , Illinois (October 25, 2010) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product."
Full News: http://www.investorideas.com/CO/BPAX/news/10252.asp
Financial Highlights
At September 30, 2010, BioSante had approximately $36M in cash
Monthly burn rate of approximately $3.5M
Investment Highlights
Financial resources to implement plan
Late stage pharmaceutical product portfolio with significant growth potential
LibiGel in three ongoing Phase III safety and efficacy clinical studies
Elestrin is FDA approved and marketed in the U.S.
Proprietary cancer vaccines in Phase II clinical trials
Focused growth strategy
Management's proven ability to gain FDA approval, implement plans and increase stockholder value
Key Products
LibiGel® - In development under an SPA for treatment of female sexual dysfunction. Three Phase III safety and efficacy clinical studies are ongoing.
ElestrinTM - FDA approved transdermal gel for treatment of hot flashes; currently marketed in the U.S. by Azur Pharma.
The Pill-PlusTM - Triple hormone contraceptive in Phase II clinical development combining hormone contraceptive and androgen. Licensed to and being developed by Pantarhei Bioscience for oral uses.
Bio-T-GelTM - In development by TEVA USA for the treatment of hypogonadism in men.
Cancer Vaccines - A portfolio of cancer vaccines in Phase II clinical trials for various cancer types, conducted at Johns Hopkins Cancer Center.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com. (three thousand per month)
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Contact BioSante Pharmaceuticals
For Media:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
or
For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com
The content from the investor Fact sheet and opinions from http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf are not the opinion of Investorideas.com or related websites.
Disclaimer: The following news is paid for by BPAX (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks800 665 0411 cvanzant@investorideas.com
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Recent Key Highlights; BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
Visit this company: www.biosantepharma.com
Point Roberts, WA, LINCOLNSHIRE, Ill - November 1, 2010 (Investorideas.com newswire, www.biotechindustrystocks.com) updates the showcase biotech stock profile for BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for investors following biotech and pharma stocks.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) reports recent news; "BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation."
The BPAX company profile is available at http://www.investorideas.com/CO/BPAX/ for interested biotech investors.
Full Media Kit at: http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf
Company Overview:
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration(FDA) Special Protocol Assessment and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in PhaseII clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies.
Lead Products – Multi-Billion Dollar Markets
BioSante is focused on developing innovative products for female sexual health and oncology. The current market for testosterone and estrogen products is approximately $2.5 billion dollars in the U.S. alone, with estimates for female sexual dysfunction (FSD) potentially adding more than $2.0 billion. In addition, the current market for hormonal contraception is approximately $3.0 billion. The market for oncology products is over $20 billion.
BioSante’s lead near term product in development is LibiGel® (testosterone gel) for the treatment of FSD. LibiGel’s clinical development program consists of two Phase III safety and efficacy trials, being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Each trial will enroll approximately 500 surgically menopausal women for six months of treatment in double-blind placebo-controlled trials. Also ongoing is one Phase III cardiovascular events-driven safety study, enrolling between 2,500 and 4,000 women with cardiovascular risk factors, on therapy for one year and then followed for an additional four years after New Drug Application (NDA) submission and potential FDA approval. To date, over 2,500 women have been enrolled in the safety study. A completed LibiGel Phase II clinical trial has shown excellent results with a significant 238% increase in the total number of satisfying sexual events. There are currently no pharmaceutical products approved for the treatment of FSD in the U.S. however over 4 million prescriptions for testosterone were written off-label by physicians for women in 2009.
BioSante’s marketed product, ElestrinTM, is FDA approved to reduce hot flashes in menopausal women. The lower of the two approved Elestrin doses is 67% lower than the lowest dose transdermal patch available for the treatment of hot flashes. Elestrin is marketed in the U.S. by Azur Pharma.
BioSante is focused primarily on LibiGel, however, the Company also is seeking future development opportunities for its cancer vaccines, which are non patient-specific therapies comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety and are administered via intradermal injections on an outpatient basis. Currently, several of BioSante’s cancer immunotherapies are in Phase II clinical trials at Johns Hopkins Cancer Center and BioSante has been granted FDA Orphan Drug designation for its pancreatic cancer, acute myloid leukemia and chronic myeloid leukemia vaccines.
Recent Company News:
BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
"LINCOLNSHIRE , Illinois (October 25, 2010) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product."
Full News: http://www.investorideas.com/CO/BPAX/news/10252.asp
Financial Highlights
At September 30, 2010, BioSante had approximately $36M in cash
Monthly burn rate of approximately $3.5M
Investment Highlights
Financial resources to implement plan
Late stage pharmaceutical product portfolio with significant growth potential
LibiGel in three ongoing Phase III safety and efficacy clinical studies
Elestrin is FDA approved and marketed in the U.S.
Proprietary cancer vaccines in Phase II clinical trials
Focused growth strategy
Management's proven ability to gain FDA approval, implement plans and increase stockholder value
Key Products
LibiGel® - In development under an SPA for treatment of female sexual dysfunction. Three Phase III safety and efficacy clinical studies are ongoing.
ElestrinTM - FDA approved transdermal gel for treatment of hot flashes; currently marketed in the U.S. by Azur Pharma.
The Pill-PlusTM - Triple hormone contraceptive in Phase II clinical development combining hormone contraceptive and androgen. Licensed to and being developed by Pantarhei Bioscience for oral uses.
Bio-T-GelTM - In development by TEVA USA for the treatment of hypogonadism in men.
Cancer Vaccines - A portfolio of cancer vaccines in Phase II clinical trials for various cancer types, conducted at Johns Hopkins Cancer Center.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com. (three thousand per month)
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Contact BioSante Pharmaceuticals
For Media:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
or
For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com
The content from the investor Fact sheet and opinions from http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf are not the opinion of Investorideas.com or related websites.
Disclaimer: The following news is paid for by BPAX (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks800 665 0411 cvanzant@investorideas.com
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Thursday, October 28, 2010
Investorideas.com - Biotech /Pharma Market Movers; (NYSE:BSX), (NASDAQ:BPAX), (OTCBB: UVFT), (NASDAQ: CELG) Stocks to Watch
Investorideas.com - Biotech /Pharma Market Movers; (NYSE:BSX), (NASDAQ:BPAX), (OTCBB: UVFT), (NASDAQ: CELG) Stocks to Watch
Boston Scientific (NYSE:BSX) Agrees to Sell Neurovascular Business to Stryker; StockTrades Over 16 Millions Shares in Morning Trading
Point Roberts, WA –October 28, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Trading Snapshot of Market Gainers for today’s trading.. Bullish trading in some of the stocks includes Boston Scientific Corporation. (NSYE: BSX), one of the top advancing stocks on the NYSE currently trading at 6.3220, up 0.0120 (0.19%) on over 16 million shares.
Biotech /Pharma Sector Trading Snapshot: (as of time of release October 28th)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) trading at $1.54, up 0.01 (0.65%)
Boston Scientific Corporation. (NYSE:BSX) trading at $6.3220, up 0.0120 (0.19%)
UV Flu Technologies, Inc. (OTCBB: UVFT) trading at $0.31 on over 500,000 shares in volume
Celgene Corporation (NASDAQ: CELG) trading at $61.52, up 2.11 (3.55%)
Biotech/Pharma Stocks Recent News;
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) News:
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Positive LibiGel® Data Monitoring Committee Recommendation
No safety issues observed, study to continue as per protocol without modifications
LINCOLNSHIRE, Ill. - October 25, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
Full news: http://www.investorideas.com/CO/BPAX/news/10252.asp
More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
UV Flu Technologies, Inc., (OTCBB: UVFT) News
UV Flu Technologies (OTCBB: UVFT) Featured in MWMarketMovers.com Analyst Report; Carried in Wednesday's Wall Street Journal
Analyst Report by Michael Williams; Published in Wall Street Journal, October 27, 2010
New York, NY – October 26, 2010 (Investorideas.com Newswire) - Biotech News Update: A 12-page analyst report on UV Flu Technologies, Inc. (OTCBB: UVFT) will be carried by The Wall Street Journal as an advertising insert in the October 27th edition of the paper. The Wall Street Journal is published by Dow Jones, a world-class publisher of financial and business newspapers, newswires, indexes, magazines, and more. The report has been authored by Michael Williams Market Movers and can also be found online by visiting www.MWMarketMovers.com.
Full news: http://www.investorideas.com/CO/UVFT/news/10261.asp
More news - Visit the UVFT showcase on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com
Boston Scientific Corporation. (NYSE:BSX)
Recent News; Boston Scientific Agrees to Sell Neurovascular Business to Stryker
“Boston Scientific Corporation today announced the execution of a definitive agreement under which Stryker Corporation will acquire Boston Scientific's Neurovascular business. The purchase price is $1.5 billion, payable in cash, of which $1.4 billion is payable at closing and $100 million will be payable following the closing and upon the occurrence of the commercialization of the next-generation Target™ Detachable Coils and the transfer or separation of certain manufacturing facilities, which is anticipated to occur over a period of approximately 24 months. The Company expects to record a gain upon closing in excess of $500 million, excluding any impact of the receipt of future milestone payments. Total after-tax proceeds, assuming the achievement of these milestones, are expected to be approximately $1.2 billion. The Company expects to allocate approximately half of the net proceeds to acquisitions and the remainder to the retirement of pre-payable debt. The transaction is expected to close before the end of the year, subject to receipt of regulatory clearances and satisfaction of other customary conditions. As a result of the divestiture, the Company expects 2011 earnings per share to be diluted by approximately four to six cents on both a GAAP and adjusted basis.”
Full Article: http://finance.yahoo.com/news/Boston-Scientific-Agrees-to-prnews-3242744555.html?x=0&.v=1
About Boston Scientific Corporation. (NYSE:BSX): Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Research other biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Sign up for free stock alerts on biotech stocks and other leading sectors!
http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX and UVFT ( third party on behalf of UV Flu- three thousand per month and three thousand per month BPAX) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Boston Scientific (NYSE:BSX) Agrees to Sell Neurovascular Business to Stryker; StockTrades Over 16 Millions Shares in Morning Trading
Point Roberts, WA –October 28, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Trading Snapshot of Market Gainers for today’s trading.. Bullish trading in some of the stocks includes Boston Scientific Corporation. (NSYE: BSX), one of the top advancing stocks on the NYSE currently trading at 6.3220, up 0.0120 (0.19%) on over 16 million shares.
Biotech /Pharma Sector Trading Snapshot: (as of time of release October 28th)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) trading at $1.54, up 0.01 (0.65%)
Boston Scientific Corporation. (NYSE:BSX) trading at $6.3220, up 0.0120 (0.19%)
UV Flu Technologies, Inc. (OTCBB: UVFT) trading at $0.31 on over 500,000 shares in volume
Celgene Corporation (NASDAQ: CELG) trading at $61.52, up 2.11 (3.55%)
Biotech/Pharma Stocks Recent News;
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) News:
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Positive LibiGel® Data Monitoring Committee Recommendation
No safety issues observed, study to continue as per protocol without modifications
LINCOLNSHIRE, Ill. - October 25, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
Full news: http://www.investorideas.com/CO/BPAX/news/10252.asp
More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
UV Flu Technologies, Inc., (OTCBB: UVFT) News
UV Flu Technologies (OTCBB: UVFT) Featured in MWMarketMovers.com Analyst Report; Carried in Wednesday's Wall Street Journal
Analyst Report by Michael Williams; Published in Wall Street Journal, October 27, 2010
New York, NY – October 26, 2010 (Investorideas.com Newswire) - Biotech News Update: A 12-page analyst report on UV Flu Technologies, Inc. (OTCBB: UVFT) will be carried by The Wall Street Journal as an advertising insert in the October 27th edition of the paper. The Wall Street Journal is published by Dow Jones, a world-class publisher of financial and business newspapers, newswires, indexes, magazines, and more. The report has been authored by Michael Williams Market Movers and can also be found online by visiting www.MWMarketMovers.com.
Full news: http://www.investorideas.com/CO/UVFT/news/10261.asp
More news - Visit the UVFT showcase on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com
Boston Scientific Corporation. (NYSE:BSX)
Recent News; Boston Scientific Agrees to Sell Neurovascular Business to Stryker
“Boston Scientific Corporation today announced the execution of a definitive agreement under which Stryker Corporation will acquire Boston Scientific's Neurovascular business. The purchase price is $1.5 billion, payable in cash, of which $1.4 billion is payable at closing and $100 million will be payable following the closing and upon the occurrence of the commercialization of the next-generation Target™ Detachable Coils and the transfer or separation of certain manufacturing facilities, which is anticipated to occur over a period of approximately 24 months. The Company expects to record a gain upon closing in excess of $500 million, excluding any impact of the receipt of future milestone payments. Total after-tax proceeds, assuming the achievement of these milestones, are expected to be approximately $1.2 billion. The Company expects to allocate approximately half of the net proceeds to acquisitions and the remainder to the retirement of pre-payable debt. The transaction is expected to close before the end of the year, subject to receipt of regulatory clearances and satisfaction of other customary conditions. As a result of the divestiture, the Company expects 2011 earnings per share to be diluted by approximately four to six cents on both a GAAP and adjusted basis.”
Full Article: http://finance.yahoo.com/news/Boston-Scientific-Agrees-to-prnews-3242744555.html?x=0&.v=1
About Boston Scientific Corporation. (NYSE:BSX): Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Research other biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Sign up for free stock alerts on biotech stocks and other leading sectors!
http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX and UVFT ( third party on behalf of UV Flu- three thousand per month and three thousand per month BPAX) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Wednesday, October 27, 2010
Investorideas.com - Direct to Consumer Company, YesDTC (OTCBB: YESD.PK) Announces Infomercial for the MediPendant(TM) Medical Alarm, Airing on Six National Cable Stations
Investorideas.com - Direct to Consumer Company, YesDTC (OTCBB: YESD.PK) Announces Infomercial for the MediPendant(TM) Medical Alarm, Airing on Six National Cable Stations
Visit this company: www.yesdtc.com
SAN FRANCISCO - October 27, 2010 (Investorideas.com newswire) - Retail/ Consumer Stock News - YesDTC Holdings, Inc. (OTCBB:YESD.PK), a direct-to-consumer global distributor and marketer of consumer goods and products, reports today it will officially begin airing its new infomercial for the MediPendant(TM) personal medial alarm, by Medical Alarm Concepts Holding, Inc. (OTCBB:MDHI), beginning today on six national cable stations in addition to local broadcast stations.
The new infomercial for MediPendant(TM) is sponsored by YesDTC and is set to start airing on Wednesday October 27th on the Discovery Health channel. It will continue to run throughout the week at various times on multiple national cable stations including Discovery Health, ESPN News, Inspiration, Lifetime Movie, Tru TV and TV Land as well as on local broadcast stations such as Northwest Cable News, until the end of the month.
Following the successful conclusion of this test market run, YesDTC plans to expand programming of the infomercial nationwide in a full rollout of the MediPendant(TM) marketing campaign. The campaign will target a wide audience of viewers in the 30 to 55 year age range who have elderly parents or loved ones that could benefit from the safety and assurance the MediPendant(TM) device can provide, including access to medical and emergency response personnel and/or personal contacts within the device user's network of friends and family.
The MediPendant(TM) infomercial can also be viewed by clicking on the following link: http://vimeo.com/16188152.
About the MediPendant(TM) Personal Alarm Device
Medical Alarm Concepts(TM) offers a unique, patented, medical emergency alarm system that is different from all other personal emergency response (PERS) systems on the market today. MDHI's MediPendant(TM) product offers several revolutionary and highly desirable features, including the ability to speak and listen to the operator directly through the pendant, an extended range of mobility from the base station, which enables the user to move virtually anywhere in or around their home, and a call center staffed around the clock with EMT-certified operators. Specifically, the MediPendant(TM) system enables the device wearer to move up to 600+ feet away from the main base station, a distance that far exceeds competitive offerings on the market today that instead require the user to be within speaking distance of the base station box, a situation that may not be conducive to an emergency if the end user is not near the base station.
Additionally, MediPendant's(TM) advanced call center technology allows for three-way calling between the operator, the user, and the dispatched first responders and/or a friend and family member. Currently, no other available PERS systems offer the benefit of three-way voice conferencing directly through the pendant. Finally, EMT-certified operators are guaranteed to stay on the line with the MediPendant(TM) user until the problem is resolved or help arrives.
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. SMW's track record is impressive, with nearly $1.0 billion in revenues generated and a high profile list of industry awards and recognitions. Specifically, SMW campaigns include Tempur-Pedic, Guthy-Renker, Sony, 24-Hour Fitness, Rhino Records, HarperCollins and PureSleep, among many others. More information on YesDTC Holding can be found at www.yesdtc.com and additional information on Schulberg Media Works can be found at www.smw.tv.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Contact:
YesDTC Holdings, IncChristian Kirsebom(925) 247-6666
Visit the YESD showcase profile at Investorideas.com Request News and Info on YESD Disclosure, Disclaimer/
YESD is a paid advertising client on Investorideas.com. YESD: one time fee five thousand and thirty thousand in shares
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Visit this company: www.yesdtc.com
SAN FRANCISCO - October 27, 2010 (Investorideas.com newswire) - Retail/ Consumer Stock News - YesDTC Holdings, Inc. (OTCBB:YESD.PK), a direct-to-consumer global distributor and marketer of consumer goods and products, reports today it will officially begin airing its new infomercial for the MediPendant(TM) personal medial alarm, by Medical Alarm Concepts Holding, Inc. (OTCBB:MDHI), beginning today on six national cable stations in addition to local broadcast stations.
The new infomercial for MediPendant(TM) is sponsored by YesDTC and is set to start airing on Wednesday October 27th on the Discovery Health channel. It will continue to run throughout the week at various times on multiple national cable stations including Discovery Health, ESPN News, Inspiration, Lifetime Movie, Tru TV and TV Land as well as on local broadcast stations such as Northwest Cable News, until the end of the month.
Following the successful conclusion of this test market run, YesDTC plans to expand programming of the infomercial nationwide in a full rollout of the MediPendant(TM) marketing campaign. The campaign will target a wide audience of viewers in the 30 to 55 year age range who have elderly parents or loved ones that could benefit from the safety and assurance the MediPendant(TM) device can provide, including access to medical and emergency response personnel and/or personal contacts within the device user's network of friends and family.
The MediPendant(TM) infomercial can also be viewed by clicking on the following link: http://vimeo.com/16188152.
About the MediPendant(TM) Personal Alarm Device
Medical Alarm Concepts(TM) offers a unique, patented, medical emergency alarm system that is different from all other personal emergency response (PERS) systems on the market today. MDHI's MediPendant(TM) product offers several revolutionary and highly desirable features, including the ability to speak and listen to the operator directly through the pendant, an extended range of mobility from the base station, which enables the user to move virtually anywhere in or around their home, and a call center staffed around the clock with EMT-certified operators. Specifically, the MediPendant(TM) system enables the device wearer to move up to 600+ feet away from the main base station, a distance that far exceeds competitive offerings on the market today that instead require the user to be within speaking distance of the base station box, a situation that may not be conducive to an emergency if the end user is not near the base station.
Additionally, MediPendant's(TM) advanced call center technology allows for three-way calling between the operator, the user, and the dispatched first responders and/or a friend and family member. Currently, no other available PERS systems offer the benefit of three-way voice conferencing directly through the pendant. Finally, EMT-certified operators are guaranteed to stay on the line with the MediPendant(TM) user until the problem is resolved or help arrives.
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. SMW's track record is impressive, with nearly $1.0 billion in revenues generated and a high profile list of industry awards and recognitions. Specifically, SMW campaigns include Tempur-Pedic, Guthy-Renker, Sony, 24-Hour Fitness, Rhino Records, HarperCollins and PureSleep, among many others. More information on YesDTC Holding can be found at www.yesdtc.com and additional information on Schulberg Media Works can be found at www.smw.tv.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Contact:
YesDTC Holdings, IncChristian Kirsebom(925) 247-6666
Visit the YESD showcase profile at Investorideas.com Request News and Info on YESD Disclosure, Disclaimer/
YESD is a paid advertising client on Investorideas.com. YESD: one time fee five thousand and thirty thousand in shares
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Investorideas.com - Direct to Consumer Medical/ Biotech Stocks; YesDTC (OTCBB: YESD.PK), GENEREX BIOTECH CORP (GNBT.PK), Utah Medical Products, Inc. (NASDAQ:UTMD)
Investorideas.com - Direct to Consumer Medical/ Biotech Stocks; YesDTC (OTCBB: YESD.PK), GENEREX BIOTECH CORP (GNBT.PK), Utah Medical Products, Inc. (NASDAQ:UTMD)
SAN FRANCISCO - October 27, 2010 (Investorideas.com newswire) – Investorideas.com, a leader in sector investor research including biotech and medical stocks, reports on recent news and developments from YesDTC (OTCBB: YESD.PK) and GENEREX BIOTECH CORP (GNBT.PK) and Utah Medical Products, Inc. (NASDAQ:UTMD).
Recent news:
YesDTC (OTCBB: YESD.PK) News:
YesDTC (OTCBB: YESD.PK) Announces the Initial Airing of a New Infomercial for the MediPendant(TM) Medical Alarm
YesDTC Holdings, Inc. (OTCBB:YESD.PK), a direct-to-consumer global distributor and marketer of consumer goods and products, announced today the Company and its product partner, Medical Alarms Concepts Holding, Inc. (OTCBB:MDHI), will begin airing a new infomercial via direct response television (DRTV) for the innovative and technologically superior MediPendant(TM) medical alarm device. The airing of the infomercial marks the commencement of a new DRTV marketing campaign designed to target a wide reaching national audience.
Full News: http://www.investorideas.com/CO/YESD/news/10261.asp
GENEREX BIOTECH CORP (GNBT.PK) News:
Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
GMD's expertise in governmental & insurer reimbursement expected to be a valuable asset for Generex's diabetes platform
WORCESTER, Mass., Oct. 11 /-- Generex Biotechnology Corporation (NasdaqCM: GNBT) (www.generex.com) today announced that it has entered into a definitive agreement to acquire a majority interest (51%) in Global Medical Direct, LLC ("GMD") of Lenexa, Kansas, a nationwide Durable Medical Equipment and Pharmaceutical provider specializing in direct-to-consumer diabetes supplies and medications (www.globalmeddirect.com).
Full news see company website.
Note Generex Biotechnology Corporation (NasdaqCM: GNBT) is now trading under stock symbol
(GNBT.PK).
Utah Medical Products, Inc. Reports Financial Performance for Third Quarter 2010
SALT LAKE CITY, Oct. 21, 2010 - Utah Medical Products, Inc. (Nasdaq:UTMD - News) reports lower sales, improved profit margins and a stronger ending balance sheet for the third calendar quarter (3Q) 2010 compared to 3Q 2009.
Full news : http://finance.yahoo.com/news/Utah-Medical-Products-Inc-pz-1621271546.html?x=0&.v=1
Utah Medical markets its products through direct sales representatives, independent manufacturers representatives, specialty distributors, national hospital distribution companies, and other medical device manufacturers in the United States; and through other medical device companies and independent medical products distributors internationally
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. SMW's track record is impressive, with nearly $1.0 billion in revenues generated and a high profile list of industry awards and recognitions. Specifically, SMW campaigns include Tempur-Pedic, Guthy-Renker, Sony, 24-Hour Fitness, Rhino Records, HarperCollins and PureSleep, among many others. More information on YesDTC Holding can be found at www.yesdtc.com and additional information on Schulberg Media Works can be found at www.smw.tv.
Contact:
YesDTC Holdings, Inc
Christian Kirsebom
(925) 247-6666
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee five thousand and thirty thousand in shares
About Investorideas.com
- Investor Ideas the can change the world
Sign up for free stock alerts and news:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
SAN FRANCISCO - October 27, 2010 (Investorideas.com newswire) – Investorideas.com, a leader in sector investor research including biotech and medical stocks, reports on recent news and developments from YesDTC (OTCBB: YESD.PK) and GENEREX BIOTECH CORP (GNBT.PK) and Utah Medical Products, Inc. (NASDAQ:UTMD).
Recent news:
YesDTC (OTCBB: YESD.PK) News:
YesDTC (OTCBB: YESD.PK) Announces the Initial Airing of a New Infomercial for the MediPendant(TM) Medical Alarm
YesDTC Holdings, Inc. (OTCBB:YESD.PK), a direct-to-consumer global distributor and marketer of consumer goods and products, announced today the Company and its product partner, Medical Alarms Concepts Holding, Inc. (OTCBB:MDHI), will begin airing a new infomercial via direct response television (DRTV) for the innovative and technologically superior MediPendant(TM) medical alarm device. The airing of the infomercial marks the commencement of a new DRTV marketing campaign designed to target a wide reaching national audience.
Full News: http://www.investorideas.com/CO/YESD/news/10261.asp
GENEREX BIOTECH CORP (GNBT.PK) News:
Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
GMD's expertise in governmental & insurer reimbursement expected to be a valuable asset for Generex's diabetes platform
WORCESTER, Mass., Oct. 11 /-- Generex Biotechnology Corporation (NasdaqCM: GNBT) (www.generex.com) today announced that it has entered into a definitive agreement to acquire a majority interest (51%) in Global Medical Direct, LLC ("GMD") of Lenexa, Kansas, a nationwide Durable Medical Equipment and Pharmaceutical provider specializing in direct-to-consumer diabetes supplies and medications (www.globalmeddirect.com).
Full news see company website.
Note Generex Biotechnology Corporation (NasdaqCM: GNBT) is now trading under stock symbol
(GNBT.PK).
Utah Medical Products, Inc. Reports Financial Performance for Third Quarter 2010
SALT LAKE CITY, Oct. 21, 2010 - Utah Medical Products, Inc. (Nasdaq:UTMD - News) reports lower sales, improved profit margins and a stronger ending balance sheet for the third calendar quarter (3Q) 2010 compared to 3Q 2009.
Full news : http://finance.yahoo.com/news/Utah-Medical-Products-Inc-pz-1621271546.html?x=0&.v=1
Utah Medical markets its products through direct sales representatives, independent manufacturers representatives, specialty distributors, national hospital distribution companies, and other medical device manufacturers in the United States; and through other medical device companies and independent medical products distributors internationally
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. SMW's track record is impressive, with nearly $1.0 billion in revenues generated and a high profile list of industry awards and recognitions. Specifically, SMW campaigns include Tempur-Pedic, Guthy-Renker, Sony, 24-Hour Fitness, Rhino Records, HarperCollins and PureSleep, among many others. More information on YesDTC Holding can be found at www.yesdtc.com and additional information on Schulberg Media Works can be found at www.smw.tv.
Contact:
YesDTC Holdings, Inc
Christian Kirsebom
(925) 247-6666
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee five thousand and thirty thousand in shares
About Investorideas.com
- Investor Ideas the can change the world
Sign up for free stock alerts and news:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
Investorideas.com - Biotech/Pharma Sector Trading Snapshot; (NASDAQ: BPAX), (NASDAQ: CADX), (NASDAQ:SUPG), (OTCBB: UVFT)
Investorideas.com - Biotech/Pharma Sector Trading Snapshot; (NASDAQ: BPAX), (NASDAQ: CADX), (NASDAQ:SUPG), (OTCBB: UVFT)
Point Roberts, WA –October 27, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Trading Snapshot, as of the close October 26th. Bullish trading in some of the stocks included SuperGen, Inc.(NasdaqGM: SUPG), one of the top advancing stocks on the NASDAQ, closing at $2.82, up $ 0.49 (21.03%), followed by additional gains in after market trading.
Biotech /Pharma Sector Trading Snapshot: (as of close October 26th)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) closed at $1.57, up 0.01 (0.64%), trading as high as $1.59 on the day.
Cadence Pharmaceuticals Inc. (NASDAQ: CADX) closed at $8.9, up 0.24 (2.75%) on 445,648 shares.
SuperGen Inc. (NASDAQ:SUPG) closed at $2.82, up $ 0.49 (21.03%) on over 3.4 million shares.
UV Flu Technologies, Inc. (OTCBB: UVFT) closed at $0.3850, up 0.0250 (6.94%) on over 1.3 million shares.
Biotech/Pharma Stocks Recent News;
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) News:
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Positive LibiGel® Data Monitoring Committee Recommendation
No safety issues observed, study to continue as per protocol without modifications
LINCOLNSHIRE, Ill. - October 25, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
Full news: http://www.investorideas.com/CO/BPAX/news/10252.asp
More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
UV Flu Technologies, Inc., (OTCBB: UVFT) News
UV Flu Technologies (OTCBB: UVFT) Featured in MWMarketMovers.com Analyst Report; Carried in Wednesday's Wall Street Journal
Analyst Report by Michael Williams; Published in Wall Street Journal, October 27, 2010
New York, NY – October 26, 2010 (Investorideas.com Newswire) - Biotech News Update: A 12-page analyst report on UV Flu Technologies, Inc. (OTCBB: UVFT) will be carried by The Wall Street Journal as an advertising insert in the October 27th edition of the paper. The Wall Street Journal is published by Dow Jones, a world-class publisher of financial and business newspapers, newswires, indexes, magazines, and more. The report has been authored by Michael Williams Market Movers and can also be found online by visiting www.MWMarketMovers.com.
Full news: http://www.investorideas.com/CO/UVFT/news/10261.asp
More news - Visit the UVFT showcase on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com
SuperGen, Inc. (NASDAQ:SUPG) News:
SuperGen Reports 2010 Third Quarter Financial Results
Dacogen Royalty Revenue Increases 28% from Same Prior Year Quarter Increases Annual Royalty and Net Income Guidance for 2010
DUBLIN, Calif.—October 25, 2010 - SuperGen, Inc. (NASDAQ:SUPG ) today reported financial results for the third quarter and nine months ended September 30, 2010.
“The third quarter was another profitable one for SuperGen. Royalties from Dacogen sales increased significantly, and we ended the quarter with more than $112 million in unrestricted cash, cash equivalents and current and non-current marketable securities, and no debt. As a result, we have raised both our royalty revenue and net income guidance for 2010,” said James S.J. Manuso, Ph.D., President and CEO. “We continue to advance the development of our drugs in the clinic, and SGI-110, a novel, second-generation DNA methylation inhibitor, is on schedule to enter a first-in-human clinical trial in myelodysplastic syndromes and AML during November.”
Full News; http://finance.yahoo.com/news/SuperGen-Reports-2010-Third-bw-1951926175.html?x=0&.v=1
Research other biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Sign up for free stock alerts on biotech stocks and other leading sectors!
http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX and UVFT ( third party on behalf of UV Flu- three thousand per month and three thousand per month BPAX) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
More info:
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Point Roberts, WA –October 27, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Trading Snapshot, as of the close October 26th. Bullish trading in some of the stocks included SuperGen, Inc.(NasdaqGM: SUPG), one of the top advancing stocks on the NASDAQ, closing at $2.82, up $ 0.49 (21.03%), followed by additional gains in after market trading.
Biotech /Pharma Sector Trading Snapshot: (as of close October 26th)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) closed at $1.57, up 0.01 (0.64%), trading as high as $1.59 on the day.
Cadence Pharmaceuticals Inc. (NASDAQ: CADX) closed at $8.9, up 0.24 (2.75%) on 445,648 shares.
SuperGen Inc. (NASDAQ:SUPG) closed at $2.82, up $ 0.49 (21.03%) on over 3.4 million shares.
UV Flu Technologies, Inc. (OTCBB: UVFT) closed at $0.3850, up 0.0250 (6.94%) on over 1.3 million shares.
Biotech/Pharma Stocks Recent News;
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) News:
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Positive LibiGel® Data Monitoring Committee Recommendation
No safety issues observed, study to continue as per protocol without modifications
LINCOLNSHIRE, Ill. - October 25, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
Full news: http://www.investorideas.com/CO/BPAX/news/10252.asp
More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
UV Flu Technologies, Inc., (OTCBB: UVFT) News
UV Flu Technologies (OTCBB: UVFT) Featured in MWMarketMovers.com Analyst Report; Carried in Wednesday's Wall Street Journal
Analyst Report by Michael Williams; Published in Wall Street Journal, October 27, 2010
New York, NY – October 26, 2010 (Investorideas.com Newswire) - Biotech News Update: A 12-page analyst report on UV Flu Technologies, Inc. (OTCBB: UVFT) will be carried by The Wall Street Journal as an advertising insert in the October 27th edition of the paper. The Wall Street Journal is published by Dow Jones, a world-class publisher of financial and business newspapers, newswires, indexes, magazines, and more. The report has been authored by Michael Williams Market Movers and can also be found online by visiting www.MWMarketMovers.com.
Full news: http://www.investorideas.com/CO/UVFT/news/10261.asp
More news - Visit the UVFT showcase on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com
SuperGen, Inc. (NASDAQ:SUPG) News:
SuperGen Reports 2010 Third Quarter Financial Results
Dacogen Royalty Revenue Increases 28% from Same Prior Year Quarter Increases Annual Royalty and Net Income Guidance for 2010
DUBLIN, Calif.—October 25, 2010 - SuperGen, Inc. (NASDAQ:SUPG ) today reported financial results for the third quarter and nine months ended September 30, 2010.
“The third quarter was another profitable one for SuperGen. Royalties from Dacogen sales increased significantly, and we ended the quarter with more than $112 million in unrestricted cash, cash equivalents and current and non-current marketable securities, and no debt. As a result, we have raised both our royalty revenue and net income guidance for 2010,” said James S.J. Manuso, Ph.D., President and CEO. “We continue to advance the development of our drugs in the clinic, and SGI-110, a novel, second-generation DNA methylation inhibitor, is on schedule to enter a first-in-human clinical trial in myelodysplastic syndromes and AML during November.”
Full News; http://finance.yahoo.com/news/SuperGen-Reports-2010-Third-bw-1951926175.html?x=0&.v=1
Research other biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Sign up for free stock alerts on biotech stocks and other leading sectors!
http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX and UVFT ( third party on behalf of UV Flu- three thousand per month and three thousand per month BPAX) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
More info:
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Investorideas.com - Biotech/Pharma Stock Profile Update; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
Investorideas.com - Biotech/Pharma Stock Profile Update; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
Recent News; BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
Point Roberts, WA, LINCOLNSHIRE, Ill –October 27, 2010 (Investorideas.com Newswire, www.biotechindustrystocks.com) reports the following updates for showcase biotech stock BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Recent updates to the company profile include company news on its lead near term product LibiGel®, in addition to media kit highlights for investors.
The company reports recent news; “BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation.”
The company profile is available at http://www.investorideas.com/CO/BPAX/ for interested biotech investors.
Full Media Kit at: http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf
Company Overview:
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery as well as seeking opportunities for its 2A/Furin and other technologies.
Recent Company News:
BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
“LINCOLNSHIRE, Illinois (October 25, 2010) – BioSante Pharmaceuticals, Inc.(NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.”
Full News: http://www.investorideas.com/CO/BPAX/news/10252.asp
Lead Products – Multi-Billion Dollar Markets
BioSante is focused on developing innovative products for female sexual health and oncology. he current market for testosterone and estrogen products is approximately $2.5billion dollars in the U.S. alone, with estimates for female sexual dysfunction potentially adding more than $2.0 billion. In addition, the current market for hormonal contraception is approximately $3.0 billion. The market for oncology products also is a multi-billion dollar market. BioSante’s lead near term product in development is LibiGel® (testosterone gel) for the treatment of female sexual dysfunction (FSD). LibiGel’s clinical development program consists of two Phase III safety and efficacy trials, being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Each trial will enroll approximately 500 surgically menopausal women for six months of treatment in double-blind placebo-controlled trials. Also ongoing is one Phase III cardiovascular events-driven safety study, enrolling between 2,500 and 4,000 women with cardiovascular risk factors, on therapy for one year and then followed for an additional four years after New Drug Application (NDA) submission and potential FDA approval. A completed LibiGel Phase II clinical trial has shown excellent results with a significant 238% increase in the total number of satisfying sexual events. There are currently no pharmaceutical products approved for the treatment of FSD in the U.S. however over 4 million prescriptions for testosterone were written off-label by physicians in 2009. BioSante’s marketed product, ElestrinTM, is FDA approved to reduce hot flashes in menopausal women. The lower of the two approved Elestrin doses is 67% lower than the lowest dose transdermal patch available for the treatment of hot flashes. Elestrin is marketed in the U.S. by Azur Pharma. BioSante will focus primarily on LibiGel, BioSante’s testosterone gel in Phase III clinical development for the treatment of female sexual dysfunction (FSD). The Company also will seek future development opportunities for its cancer vaccines, which are non patient-specific therapies comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety and are administered via intradermal injections on an outpatient basis. Currently, several of BioSante’s cancer immunotherapies are in Phase II clinical trials at Johns Hopkins Cancer Center and BioSante has been granted FDA Orphan Drug designation for its pancreatic cancer, acute myeloid leukemia and chronic myeloid leukemia vaccines.
Investment Highlights
• Financial resources to implement plan
• Late stage pharmaceutical product portfolio with significant growth potential
• LibiGel in three ongoing Phase III safety and efficacy clinical studies
• Elestrin is FDA approved and marketed in the U.S.
• Proprietary cancer vaccines in Phase II clinical trials
• Proprietary CaP technology with aesthetic medicine potential
• Focused growth strategy
• Management’s proven ability to gain FDA approval, implement plans and
increase stockholder value
Financial Highlights
• At March 31, 2010, BioSante had approximately $41M in cash
• Monthly burn rate of approximately $2.5-$3.0M
Key Products
LibiGel® — In development under an SPA
for treatment of female sexual dysfunction.
Three Phase III safety and efficacy clinical
studies are ongoing.
ElestrinTM — FDA approved transdermal
gel for treatment of hot flashes; currently
marketed in the U.S. by Azur Pharma.
The Pill-PlusTM — Triple hormone
contraceptive in Phase II clinical development
combining hormone contraceptive and
androgen. Licensed to and being developed
by Pantarhei Bioscience for oral uses.
Cancer Vaccines — A portfolio of
cancer vaccines in Phase II clinical trials for
various cancer types, conducted at Johns
Hopkins Cancer Center.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com. (three thousand per month)
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Contact BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
The content from the investor Fact sheet and opinions from http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf are not the opinion of Investorideas.com or related websites.
Disclaimer: The following news is paid for by BPAX (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante
Recent News; BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
Point Roberts, WA, LINCOLNSHIRE, Ill –October 27, 2010 (Investorideas.com Newswire, www.biotechindustrystocks.com) reports the following updates for showcase biotech stock BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Recent updates to the company profile include company news on its lead near term product LibiGel®, in addition to media kit highlights for investors.
The company reports recent news; “BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation.”
The company profile is available at http://www.investorideas.com/CO/BPAX/ for interested biotech investors.
Full Media Kit at: http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf
Company Overview:
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery as well as seeking opportunities for its 2A/Furin and other technologies.
Recent Company News:
BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
“LINCOLNSHIRE, Illinois (October 25, 2010) – BioSante Pharmaceuticals, Inc.(NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.”
Full News: http://www.investorideas.com/CO/BPAX/news/10252.asp
Lead Products – Multi-Billion Dollar Markets
BioSante is focused on developing innovative products for female sexual health and oncology. he current market for testosterone and estrogen products is approximately $2.5billion dollars in the U.S. alone, with estimates for female sexual dysfunction potentially adding more than $2.0 billion. In addition, the current market for hormonal contraception is approximately $3.0 billion. The market for oncology products also is a multi-billion dollar market. BioSante’s lead near term product in development is LibiGel® (testosterone gel) for the treatment of female sexual dysfunction (FSD). LibiGel’s clinical development program consists of two Phase III safety and efficacy trials, being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Each trial will enroll approximately 500 surgically menopausal women for six months of treatment in double-blind placebo-controlled trials. Also ongoing is one Phase III cardiovascular events-driven safety study, enrolling between 2,500 and 4,000 women with cardiovascular risk factors, on therapy for one year and then followed for an additional four years after New Drug Application (NDA) submission and potential FDA approval. A completed LibiGel Phase II clinical trial has shown excellent results with a significant 238% increase in the total number of satisfying sexual events. There are currently no pharmaceutical products approved for the treatment of FSD in the U.S. however over 4 million prescriptions for testosterone were written off-label by physicians in 2009. BioSante’s marketed product, ElestrinTM, is FDA approved to reduce hot flashes in menopausal women. The lower of the two approved Elestrin doses is 67% lower than the lowest dose transdermal patch available for the treatment of hot flashes. Elestrin is marketed in the U.S. by Azur Pharma. BioSante will focus primarily on LibiGel, BioSante’s testosterone gel in Phase III clinical development for the treatment of female sexual dysfunction (FSD). The Company also will seek future development opportunities for its cancer vaccines, which are non patient-specific therapies comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety and are administered via intradermal injections on an outpatient basis. Currently, several of BioSante’s cancer immunotherapies are in Phase II clinical trials at Johns Hopkins Cancer Center and BioSante has been granted FDA Orphan Drug designation for its pancreatic cancer, acute myeloid leukemia and chronic myeloid leukemia vaccines.
Investment Highlights
• Financial resources to implement plan
• Late stage pharmaceutical product portfolio with significant growth potential
• LibiGel in three ongoing Phase III safety and efficacy clinical studies
• Elestrin is FDA approved and marketed in the U.S.
• Proprietary cancer vaccines in Phase II clinical trials
• Proprietary CaP technology with aesthetic medicine potential
• Focused growth strategy
• Management’s proven ability to gain FDA approval, implement plans and
increase stockholder value
Financial Highlights
• At March 31, 2010, BioSante had approximately $41M in cash
• Monthly burn rate of approximately $2.5-$3.0M
Key Products
LibiGel® — In development under an SPA
for treatment of female sexual dysfunction.
Three Phase III safety and efficacy clinical
studies are ongoing.
ElestrinTM — FDA approved transdermal
gel for treatment of hot flashes; currently
marketed in the U.S. by Azur Pharma.
The Pill-PlusTM — Triple hormone
contraceptive in Phase II clinical development
combining hormone contraceptive and
androgen. Licensed to and being developed
by Pantarhei Bioscience for oral uses.
Cancer Vaccines — A portfolio of
cancer vaccines in Phase II clinical trials for
various cancer types, conducted at Johns
Hopkins Cancer Center.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com. (three thousand per month)
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Contact BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
The content from the investor Fact sheet and opinions from http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf are not the opinion of Investorideas.com or related websites.
Disclaimer: The following news is paid for by BPAX (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante
Subscribe to:
Posts (Atom)